For more than 80 years, Beckman Coulter has been a trusted partner for laboratory professionals, helping to advance scientific research and patient care.
For more than 80 years, Beckman Coulter has been a trusted partner for laboratory professionals, helping to advance scientific research and patient care.
IDBS provides purpose-built software solutions to address the data management challenges prominent across the BioPharma lifecycle and supply chain.
Leica Microsystems develops leading-edge microscopes and scientific instruments to power technological advances and touch lives in meaningful ways.
Molecular Devices provides high-performance bioanalytical measurement solutions for life science research, pharmaceutical and biotherapeutic development.
Phenomenex chromatography solutions accelerate science and give researchers the tools they require to improve global health and wellbeing.
SCIEX is a global leader in mass spectrometry and a trusted partner to scientists and lab analysts worldwide.
Aldevron provides critical nucleic acids and proteins used to make gene and cell therapies, gene editing technologies, DNA and RNA vaccines.
Cytiva and Pall Life Sciences have come together to deliver the breadth, depth, and scale researchers and biopharma need to advance future therapeutics—from discovery to delivery.
IDT manufactures products used in diagnostic tests for many forms of cancer and most inherited and infectious diseases.
| TIme | Description | Room / Location | Presenter |
| 8:30 AM – 12:00 PM EST | Level Up Your 3D Cell Culture: From Research to High Throughput | Room 152 | Hilary Sherman, BS (she/her/hers) – Corning Life Sciences
Oksana Sirenko, PhD (she/her/hers) – Molecular Devices
Angeline Lim, PhD – Molecular Devices |
| TIme | Description | Room / Location | Presenter |
| 4:30 PM – 4:50 PM EST | A novel, automated workflow for top clone selection in cell line development | Solutions Spotlight Theater (Exhibition 1290) | Jason Lanie, MBA, MS, BS (he/him/his) –Beckman Coulter Life Sciences |
| 12:00 PM – 1:00 PM EST | Development of a Global Reporter on Transcript Abundance (GRETA) for drug discovery and development | 104B | Tim Read, PhD, BS (he/him/his) – Arpeggio Biosciences
John Fuller, PhD (he/him/his) – Beckman Coulter Life Sciences |
| TIme | Description | Room / Location | Presenter |
| 8:30 AM – 10:00 AM EST | Exhibitor Tutorial - SCIEX | Room 102A | Exhibitor Tutorial - Sponsored By SCIEX |
| 12:00 PM – 1:00 PM EST | Exhibitor Tutorial - Abcam | Room 152 | Exhibitor Tutorial - Sponsored by Abcam |
| 12:00 PM – 1:00 PM EST | How to gain more insights from more clones in cell line development
More and more therapies based on monoclonal antibodies are rapidly gaining importance in the pharmaceutical market. The timely development of new therapeutic antibodies is closely linked to cell line development. Faster and more efficient development of new stable cell lines that produce sufficient titer is key to identifying new treatments for various cancers and auto immune diseases—to name only a few conditions—because it significantly impacts time to market. Screening for the best clones requires a high-throughput approach, and ideally occurs under near-production conditions (fed-batch). However, a lack of automation and effective integration of lab instruments is often one of the main bottlenecks, which limits the number of clones screened, and hence the possibility of overlooking what could be the best candidates. In addition to the manual handling of cultivation vessels in clone screening, another error-prone task is the handling of samples to measure viable cell density as well as the antibody titer. A time-resolved dataset of these parameters is needed to properly evaluate each clone and make a fact-based decision about which clones to transfer to larger scales. In this talk, we show data from cultivations with CHO clones, and present an automated workflow for cultivation and analysis of these clones. | Room 104B | Sebastian Hofzumahaus, PhD, BS (he/him/his) – Beckman Coulter Life Sciences GmbH |
| 12:00 PM – 1:00 PM EST | The future of cell culture: Transforming the complexities of 3D cell culture into reliable and translatable science
The majority of drugs fail in the later stages of the drug development pipeline and in clinical trials because of insufficient predictivity of cell models used to screen drug candidates. Organoids show great promise as a game-changer in disease modeling and drug screening since they better resemble tissue structure and functionality, and show more predictive response to drugs. However, challenges associated with using organoids, such as assay complexity, reproducibility, and the ability to scale up have limited their widespread adoption as a primary screening method in drug discovery. | Room 102A | Oksana Sirenko, PhD (she/her/hers) – Molecular Devices
Felix Spira – Molecular Devices |
| 2:00 PM – 2:20 PM EST | Z-X-Y: Integrating acoustic dispensing with droplet microfluidics for accelerating gene editing workflows | Solutions Spotlight Theater (Exhibition 1290) | Hugo Sinha, MS, BS (he/him/his) – DropGenie Beckman Coulter Life Sciences |
| 2:00 PM – 3:00 PM EST | Exhibitor Tutorial - Genedata | Room 102B | Exhibitor Tutorial - Sponsored By Genedata |
| TIme | Description | Room / Location | Presenter |
| 11:00 AM – 11:30 AM EST | Catalyzing Confidence: A Comprehensive Strategy for Enhancing DEL Hit Validation in Drug Discovery | Room 210C | Stefan Geschwindner, PhD, PhD – AstraZeneca R&D |